NCT04340180View on ClinicalTrials.gov

Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 14, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

December 30, 2025

Conditions
Breast Benign TumorBreast Malignant Tumor
Interventions
DRUG

Standard of Care (SOC) gadolinium Breast MRI

Standard of Care (SOC) gadolinium Breast MRI

DRUG

reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.

reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.

Trial Locations (1)

35249

The Kirklin Clinic, Birmingham

Sponsors

Collaborators (1)

Bracco Corporate
All Listed Sponsors
collaborator

Bracco Corporate

INDUSTRY

lead

University of Alabama at Birmingham

OTHER